Search Results - b-cell+maturation+antigen

2 Results Sort By:
Fully-human Heavy-chain-only Anti-B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptors (CARs)
Abstract: Immortalization of plasma cells leads to plasma cell malignancy diseases such as multiple myeloma (MM). B-cell maturation antigen (BCMA) is a protein that is preferentially expressed by malignant and normal B cells and plasma cells, butnot on other cells in the body. This limited expression profile suggests that BCMA is a promising target...
Published: 8/14/2024   |   Inventor(s): James Kochenderfer, Norris Lam, Benjamin Buelow
Keywords(s): act, adoptive cell therapy, B-cell Malignancies, B-cell Maturation Antigen, BCMA, BIOLOGIC, CANCER, CAR, chimeric antigen receptor, Hodgkin Lymphoma, Hodgkin’s Lymphoma, Kochenderfer, Mm, MULTIPLE MYELOMA, Non-Hodgkin Lymphoma, Non-Hodgkin’s Lymphoma, Plasma Cell Malignancies
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
New Class of Immunotoxins with Extended Half-Life and High Anti-Tumor Activity
Abstract: Recombinant immunotoxins (RITs) constitute a promising solution to hematologic cancers (e.g., Multiple Myeloma [MM]). RITs are chimeric proteins composed of a targeting domain fused to a bacterial toxin. Upon binding to a cancer cell displaying the target antigen, RITs are internalized, metabolized and the released toxin kills the cell. While...
Published: 5/21/2024   |   Inventor(s): Ira Pastan
Keywords(s): Abd, Albumin Binding Domain, antibody conjugate, B-cell Maturation Antigen, BCMA, Hematologic Cancer, Mm, MULTIPLE MYELOMA, Pastan, Recombinant Immunotoxin, Rit
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology